SONG; Yeon Jung

Patent Applications and Registrations

Patent applications and USPTO patent grants for SONG; Yeon Jung.The latest application filed is for "antibody binding to fcrn for treating autoimmune diseases".

Company Profile

5.10.13

SONG; Yeon Jung - Gyeonggi-do KR
Song; Yeon Jung - Suwon-si KR
Song; Yeon Jung - Yongon-si N/A KR
Song; Yeon Jung - Yongin-si KR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Antibody Binding To Fcrn For Treating Autoimmune Diseases App 20200109201 - KIM; Sung Wuk ; et al.	2020-04-09
Antibody binding to FcRn for treating autoimmune diseases Grant 10,544,226 - Kim , et al. Ja	2020-01-28
Antibody binding to FcRn for treating autoimmune diseases Grant 10,336,825 - Kim , et al.	2019-07-02
Antibody Binding To Fcrn For Treating Autoimmune Diseases App 20190135917 - KIM; Sung Wuk ; et al.	2019-05-09
FcRn-specific human antibody and composition for treatment of autoimmune diseases Grant 10,280,207 - Kim , et al.	2019-05-07
Pharmaceutical composition comprising N1-cyclic amine-N5-substituted biguanide derivatives as an ingredient for preventing or treating fibrosis Grant 10,058,558 - Kim , et al. August 28, 2	2018-08-28
Antibody Binding To Fcrn For Treating Autoimmune Diseases App 20170210805 - Kim; Sung Wuk ; et al.	2017-07-27
Antibody Binding To Fcrn For Treating Autoimmune Diseases App 20170210801 - Kim; Sung Wuk ; et al.	2017-07-27
Uses of modified human tumor necrosis factor receptor-1 polypeptide Grant 9,580,490 - Kim , et al. February 28, 2	2017-02-28
Fcrn-specific Human Antibody And Composition For Treatment Of Autoimmune Diseases App 20160137713 - Kim; Sung Wuk ; et al.	2016-05-19
Pharmaceutical Composition Comprising N1-cyclic Amine-n5-substituted Biguanide Derivatives As An Ingredient For Preventing Or Treating Fibrosis App 20160101112 - Kim; Sung Wuk ; et al.	2016-04-14
Uses Of Modified Human Tumor Necrosis Factor Receptor-1 Polypeptide App 20150119338 - Kim; Sung Wuk ; et al.	2015-04-30
Modified human tumor necrosis factor receptor-I polypeptide or fragment thereof, and method for preparing same Grant 8,895,500 - Kim , et al. November 25, 2	2014-11-25
Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same Grant 8,754,037 - Kim , et al. June 17, 2	2014-06-17
Modified Human Tumor Necrosis Factor Receptor-i Polypeptide Or Fragment Thereof, And Method For Preparing Same App 20130237472 - Kim; Sung Wuk ; et al.	2013-09-12
Modified Human Tumor Necrosis Factor Receptor-1 Polypeptide Or Fragment Thereof, And Method For Preparing Same App 20120277142 - Kim; Sung Wuk ; et al.	2012-11-01
Modified Human Tumor Necrosis Factor Receptor-1 Polypeptide Or Fragment Thereof, And Method For Preparing Same App 20120251486 - Kim; Sung Wuk ; et al.	2012-10-04
Modified Human Thrombopoietin Polypeptide Fragment And Manufacturing Method Thereof App 20110294733 - Kim; Sung Wuk ; et al.	2011-12-01
Antifungal triazole derivatives Grant 7,968,579 - Park , et al. June 28, 2	2011-06-28
Novel Antifungal Triazole Derivatives App 20080287440 - Park; Joon Seok ; et al.	2008-11-20

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.